Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Resectable MSI-H/dMMR Colon Cancer
NCT07412613Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in colon cancer, sponsored by Akeso, Inc.. Started Apr 2026; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07412613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412613.